AU3282900A - Target cell-specific, multivalent proteins (mvp) - Google Patents

Target cell-specific, multivalent proteins (mvp)

Info

Publication number: AU3282900A
Authority: AU; Australia
Prior art keywords: mvp; specific; target cell; multivalent proteins; multivalent
Prior art date: 1999-03-10
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Abandoned

Application number

AU32829/00A

Inventor

Roland Kontermann

Rolf Muller

Dirk Nettelbeck

Hans-Harald Sedlacek

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Sanofi Aventis Deutschland GmbH

Original Assignee

Aventis Pharma Deutschland GmbH

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-03-10

Filing date

2000-02-26

Publication date

2000-09-28

2000-02-26 Application filed by Aventis Pharma Deutschland GmbH filed Critical Aventis Pharma Deutschland GmbH

2000-09-28 Publication of AU3282900A publication Critical patent/AU3282900A/en

Status Abandoned legal-status Critical Current

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/081—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from DNA viruses
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Immunology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Molecular Biology (AREA)
Rheumatology (AREA)
Neurology (AREA)
Physical Education & Sports Medicine (AREA)
Orthopedic Medicine & Surgery (AREA)
Neurosurgery (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Dermatology (AREA)
Toxicology (AREA)
Zoology (AREA)
Gastroenterology & Hepatology (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Biomedical Technology (AREA)
Hematology (AREA)
Diabetes (AREA)
Transplantation (AREA)
Pain & Pain Management (AREA)
Virology (AREA)

AU32829/00A 1999-03-10 2000-02-26 Target cell-specific, multivalent proteins (mvp) Abandoned AU3282900A (en)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
DE19910419A DE19910419A1 (en)	1999-03-10	1999-03-10	Target Cell-Specific Multivalent Proteins (MVP)
DE19910419		1999-03-10
PCT/EP2000/001612 WO2000053790A1 (en)	1999-03-10	2000-02-26	Target cell-specific, multivalent proteins (mvp)

Publications (1)

Publication Number	Publication Date
AU3282900A true AU3282900A (en)	2000-09-28

Family

ID=7900295

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AU32829/00A Abandoned AU3282900A (en)	1999-03-10	2000-02-26	Target cell-specific, multivalent proteins (mvp)

Country Status (5)

Country	Link
EP (1)	EP1161550A1 (en)
JP (1)	JP2002537847A (en)
AU (1)	AU3282900A (en)
DE (1)	DE19910419A1 (en)
WO (1)	WO2000053790A1 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
BR0209074A (en)	2001-04-23	2004-08-10	Mallinckrodt Inc	Radioactive glycosylated octreotide derivatives with tc and re markers
PL195457B1 (en) *	2002-08-05	2007-09-28	Zaklady Farm Polpharma Sa	Expression cassette, bi-cistron plasmide vector, pharmaceutical composition and their application
DE10259713A1 (en) *	2002-12-19	2004-07-08	Johannes-Gutenberg-Universität Mainz	Process for the stabilization of expression and improvement of the specific effector function of single chain antigen-recognizing genetic constructs (scARC) and corresponding mutated MDM2 protein specific scT cell receptors
US7893244B2 (en)	2005-04-12	2011-02-22	Intradigm Corporation	Composition and methods of RNAi therapeutics for treatment of cancer and other neovascularization diseases
CA2604441A1 (en)	2005-04-12	2006-10-19	Intradigm Corporation	Composition and methods of rnai therapeutics for treatment of cancer and other neovascularization diseases
AU2016206486A1 (en) *	2015-01-16	2017-07-20	The Board Of Trustees Of The Leland Stanford Junior University	VEGF variant polypeptide compositions

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB9012995D0 (en) *	1990-06-11	1990-08-01	Celltech Ltd	Multivalent antigen-binding proteins
IL106760A (en) *	1992-08-25	1999-12-31	Miles Inc	Protein-nucleic acid hybrid construct for translocating an exogenous nucleic acid into a target cell and nucleus
DE19649645A1 (en) *	1996-11-29	1998-06-04	Hoechst Ag	Multiple functional ligand system for target cell-specific transfer of nucleotide sequences
CZ121599A3 (en) *	1998-04-09	1999-10-13	Aventis Pharma Deutschland Gmbh	A single chain molecule binding several antigens, a method for its preparation, and a drug containing the molecule

1999
- 1999-03-10 DE DE19910419A patent/DE19910419A1/en not_active Withdrawn
2000
- 2000-02-26 EP EP00910717A patent/EP1161550A1/en not_active Withdrawn
- 2000-02-26 JP JP2000603411A patent/JP2002537847A/en not_active Withdrawn
- 2000-02-26 WO PCT/EP2000/001612 patent/WO2000053790A1/en not_active Ceased
- 2000-02-26 AU AU32829/00A patent/AU3282900A/en not_active Abandoned

Also Published As

Publication number	Publication date
WO2000053790A1 (en)	2000-09-14
DE19910419A1 (en)	2000-09-21
JP2002537847A (en)	2002-11-12
EP1161550A1 (en)	2001-12-12

Publication	Publication Date	Title
AU2001232799A1 (en)	2001-08-20	Protein c derivatives
AU6906800A (en)	2001-03-13	Membrane associated proteins
AU6114700A (en)	2001-02-13	Novel system for the sequential, directional cloning of multiple dna sequences
AU6045900A (en)	2000-12-12	Interaction-activated proteins
AUPQ524000A0 (en)	2000-06-15	Anti-missile missiles
AU2445601A (en)	2001-07-03	Mammalian protein phosphatases
AU2001295777A1 (en)	2002-05-06	Target
AU2002232803A1 (en)	2002-05-27	Expression system for recombinant proteins
AU3282900A (en)	2000-09-28	Target cell-specific, multivalent proteins (mvp)
AU2001242625A1 (en)	2001-10-08	Gene sequence
AU4188500A (en)	2000-11-17	Protein c derivatives
AU4081000A (en)	2000-11-14	Uncoupling proteins
AU2472501A (en)	2001-07-16	Methods for protein transfer
AU1751801A (en)	2001-05-30	Protein c derivatives
AU1881200A (en)	2000-08-29	Novel proteins
AU4214800A (en)	2000-10-23	Vesicle associated proteins
AU2061201A (en)	2001-06-25	Mammalian dishevelled-associated proteins
AU2002239747A1 (en)	2002-06-03	Cystoskeleton-associated proteins
AU6983000A (en)	2001-03-05	Chimeric proteins
AU2001269257A1 (en)	2002-02-13	Target face
AU6911300A (en)	2001-03-13	Isomerase proteins
AU7904200A (en)	2001-04-17	Munition
AU5034200A (en)	2000-12-12	Oxidoreductase proteins
AU1540701A (en)	2001-06-12	Novel protein
AU4147200A (en)	2001-07-16	Cancer cell-specific gene expression system

Legal Events

Date	Code	Title	Description
2002-02-07	MK6	Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase